Literature DB >> 19318319

Peripheral cytokine profile in Chilean patients with Crohn's disease and ulcerative colitis.

Caroll J Beltrán1, Enzo Candia, Benjamín Erranz, Carolina Figueroa, Maria J Gonzalez, Rodrigo Quera, Marcela A Hermoso.   

Abstract

Crohn's disease (CD) and ulcerative colitis (UC) belong to the group of inflammatory bowel diseases (IBD), with complex ethiopathogenic factors that include an unbalanced immune and inflammatory response to commensal and food antigens. The differential diagnosis between CD and UC is performed using clinical, endoscopic, histopathological, serological and radiological methods; however between 10-15% of IBD patients are diagnosed as "unclassified colitis". Further research into IBD is necessary in order to develop additional diagnostic tools. The aim of this work was to see if the Th1, Th17 or Th2 immune pattern, represented by CD4+ lymphocytes producing IFN-gamma, IL-17 and IL-5 or IL-13, respectively (CD4/IFN-gamma+, CD4/IL-17+,CD4/IL-5+ or, CD4/IL13+), are useful peripheral markers which can be used to differentiate between UC and CD. Peripheral blood samples were taken from IBD patients from the Clinic Hospital of the University of Chile. The percentage of IFN-gamma-, IL-17-, IL-5- or IL-13-expressing CD4+ cells was determined by flow cytometry in phorbol ester- (PMA) and calcymycin-activated blood samples. The percentages of the CD4+ cell populations producing each cytokine were compared between UC and CD. IFN-gamma production by CD4+ lymphocytes was significantly higher in CD compared to UC and the control. The percentage of IL-17-expressing cells was significantly higher in CD patients compared to to the control; however, there were no differences between UC and CD; or between UC and healthy individuals. No significant differences were observed between the different groups as regards the representative Th2 cytokines. This study suggests that, under pathogenic conditions, several immune profiles may be operating, in the development of IBD. Although peripheral IFN-gamma and IL-17 expression, as indicators of the immune pattern, may help in the diagnosis of IBD, other cytokines and adaptive immune markers should be analyzed to allow better differentiation between the two entities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19318319     DOI: 10.1684/ecn.2009.0142

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  6 in total

1.  Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies.

Authors:  Vaishali L Chudasama; Anup Zutshi; Pratap Singh; Anson K Abraham; Donald E Mager; John M Harrold
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-01-06       Impact factor: 2.745

Review 2.  Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?

Authors:  Guanglin Cui; Jon Florholmen; Rasmus Goll
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

Review 3.  Intestinal effector T cells in health and disease.

Authors:  Craig L Maynard; Casey T Weaver
Journal:  Immunity       Date:  2009-09-18       Impact factor: 31.745

4.  Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease.

Authors:  Cailin M Wilke; Lin Wang; Shuang Wei; Ilona Kryczek; Emina Huang; John Kao; Yanwei Lin; Jingyuan Fang; Weiping Zou
Journal:  J Transl Med       Date:  2011-12-16       Impact factor: 5.531

5.  Interleukin-19 impairment in active Crohn's disease patients.

Authors:  Elisabet Cantó; Esther Garcia Planella; Carlos Zamora-Atenza; Juan Camilo Nieto; Jordi Gordillo; Ma Angels Ortiz; Isidoro Metón; Elena Serrano; Esteban Vegas; Orlando García-Bosch; Cándido Juárez; Sílvia Vidal
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

6.  Sex differences in obesity development in pair-fed neuronal lipoprotein lipase deficient mice.

Authors:  Hong Wang; Yongping Wang; Matthew D Taussig; Robert H Eckel
Journal:  Mol Metab       Date:  2016-05-31       Impact factor: 7.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.